TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Salipro Biotech AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
572
|
538
|
671 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-396
|
-384
|
-216 |
| EBITDA |
-333
|
-334
|
-166 |
| Total assets |
940
|
1,408
|
1,764 |
| Current assets |
396
|
860
|
1,282 |
| Current liabilities |
127
|
156
|
132 |
| Equity capital |
813
|
1,252
|
1,631 |
| - share capital |
6
|
6
|
6 |
| Employees (average) |
8
|
9
|
7 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
86.5%
|
88.9%
|
92.5% |
| Turnover per employee |
72
|
60
|
96 |
| Profit as a percentage of turnover |
-69.2%
|
-71.4%
|
-32.2% |
| Return on assets (ROA) |
-42.1%
|
-27.3%
|
-12.2% |
| Current ratio |
311.8%
|
551.3%
|
971.2% |
| Return on equity (ROE) |
-48.7%
|
-30.7%
|
-13.2% |
| Change turnover |
52
|
-135
|
266 |
| Change turnover % |
10%
|
-20%
|
66% |
| Chg. No. of employees |
-1
|
2
|
1 |
| Chg. No. of employees % |
-11%
|
29%
|
17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.